CoronaryAtlas logo
CoronaryAtlas
Beta-2-glycoprotein I
Pathway / Platelet adhesion & activation

Beta-2-glycoprotein I

APOHprotein

Beta-2-glycoprotein I complexes with oxidized LDL in atherosclerotic lesions and is targeted by antiphospholipid antibodies to activate thrombosis.

Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencehigh
RationaleForms oxLDL complexes; antiphospholipid antibody target in thrombotic syndrome.
Also acts inCoagulation / thrombus, Vascular inflammation, Lipid entry/oxidation
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000091583

Type I vs Type II discrimination

ScoresType-II-associated
R — rupture / Type-I
—
C — confounder / Type-II
50
A — assay feasibility
68
E — evidence strength
52
T1DI (composite)
12
Specificity differential (R−C)-35
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmian/a
5hypoxemia / respiratory failuremag 1
6hypertensive emergencyn/a
7high-demand / peri-operative stressn/a
Coverage: 2/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 2 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(4)